Susan Galbraith: So thanks for the question, Seamus. So the data to support the TRP-2 biomarker comes from multiple different settings, including the early combination data. But yes, absolutely, we’ll be looking at the Coping01 data as well when that reads out. So I do think that, that’s important. We do know that TROP2 is highly expressed in many different cancers. But I think optimizing for the expression and heterogeneity of expression is something that can potentially identify the patient populations that are more likely to respond are more likely to get a durable benefit. I think that’s an important consideration, not just in lung cancer but across other potential indications.
Pascal Soriot: Leon, do you want to cover the Cercon question? Thanks, Susan.
Leon Wang: Yes. Silicon is quite a big product getting into repeat tender loss. And I think the last one is the Pulmicort. So actually, we are launching new products speeding up our portfolio and launch to offset these losses. But I think Seneca is a quantic disease product. It has 20 million, 30 million patients, actually the largest number of patients in China of Astrani products in silicon. So actually, the price is low and has 3 indications and the corn hard disease and hypertension and heart failure. So actually, it’s a quite a good product in classical and branded. So we will do a lot of consumerization and making sure loyal user of Selten will still be sticky got and also the lens of treatment for silicon is quite good patients stick to it because of the heart rate.
So we also will do a lot of digital channel education. And also, we have a quite successful business in China on retail pharmacy. So, I think it will first drop quite significantly but gradually, it will pick up because more and more patients will take the drug for long term and loyal customer will stay with the product. And we will still be promoting a lot of other cardiovascular products within the hospital. And Astronics is the number 1 company total but also number 1 company in cardiovascular renal space. So we have a Rock Forxiga and so many other products still quite active. And also we have a new product in hypertension which is coming. So, I think all in all, I’m not too pessimistic about the Selco future.
Pascal Soriot: Thank you, Leon. Just to illustrate to tell on saying, look at the Crestor in China which we have consumerized and the price is low, as Leon said, those are chronic conditions and patients take these products over a long period of time. We have very extensive capabilities online and pharmacy-based activities. So we think we can consume us salon, a little bit like we’ve done with Cristal.
Ruud Dobber: Regarding the next Japan question, we have lost the exclusivity in Japan late last year. And instantly, we have seen generics coming into the marketplace. So the expectation for 2023 is a sharp decline in our exam business in Japan.
Pascal Soriot: Thank you. Jo Walton, Credit Suisse. Jo, over to you.
Jo Walton: Thank you. A couple, please. On Tagrisso, I believe, Pascal, you’ve said that you’re confident that you can keep going with that despite IRA, perhaps because of orphan drug elements. I wonder if you could tell us a little bit about that because Tagrisso, I guess, could be mentioned as one of the drugs when they give the list later this year. Aradhana, I wonder if I could ask an earlier question in a different way, just in terms of COVID, if you could give us some sense of how much COVID contributed to your earnings in 2022, we can all then make our decision about what we think will be in ’23. It’s just that sort of level that there has been today. And my final question is just on your confidence in being able to control your operating costs.
